

# JOHN R CROCHET, JR, MD, FACOG

Reproductive Endocrinology and Infertility  
Obstetrics and Gynecology

## Center of Reproductive Medicine

1015 Medical Center Boulevard, Suite 2100

Webster, Texas 77598

P 281.332.0073      jcrochet@infertilitytexas.com

F 281.557.5837      www.infertilitytexas.com

## WORK EXPERIENCE

- 2017-Present      **Adjunct Associate Professor**, the Department of Obstetrics and Gynecology, the University of Texas Medical Branch, Galveston, Texas
- 2012-Present      **Administrative Director, Director of Third Party Reproduction, Reproductive Endocrinologist**, Center of Reproductive Medicine, Houston, Clear Lake, Beaumont, and Pearland, Texas
- 2009-2012      **Fellow**, Division of Reproductive Endocrinology and Fertility  
**Clinical Associate**, Department of Obstetrics and Gynecology  
Duke University Medical Center, Durham, North Carolina
- 2005-2009      **Resident**, Department of Obstetrics and Gynecology  
Parkland Health and Hospital System, Dallas, Texas

## TRAINING AND EDUCATION

- 2009-2012      **Fellowship, Reproductive Endocrinology and Fertility**  
Duke University Medical Center, Durham, North Carolina
- 2005-2009      **Residency, Obstetrics and Gynecology**  
The University of Texas Southwestern Medical Center, Dallas, Texas
- 2001-2005      **Doctor of Medicine**  
The University of Texas Medical Branch, Galveston, Texas
- 1997-2001      **Bachelor of Science, Genetics, *Magna Cum Laude***  
Texas A&M University, College Station, Texas

## AWARDS

- 2017      Excellence in Residency Education, University of Texas – Medical Branch
- 2017      Super Doctors Rising Star, *Texas Monthly*
- 2017      Top Docs, *H-Texas* magazine

2016	Super Doctors Rising Star, <i>Texas Monthly</i>
2016	Top Doctors, <i>Houstonia</i> magazine
2015	Super Doctors Rising Star, <i>Texas Monthly</i>
2015	Top Doctors, <i>Houstonia</i> magazine
2013	Top Docs, <i>H-Texas</i> magazine
2009	Outstanding Senior Resident Teacher, UT Southwestern
2009	Excellence in Laparoscopic and Endoscopic Surgery, UT Southwestern
2009	Excellence in Ultrasonography, UT Southwestern
2008	Medical Student Teaching Commendation, UT Southwestern
2007	Wyeth Resident Reporter, ASRM 63 <sup>rd</sup> Annual Meeting
2007	CREOG Academic Excellence, UT Southwestern
2007	Medical Student Teaching Commendation, UT Southwestern
2005	Excellence in Patient-Oriented Research, NSRF
2005	Second Place Overall Poster Presentation, NSRF
2000-2001	Charles Henry Hardin Founder's Scholarship, Beta Theta Pi
1998-2001	Educate Our Children Scholarship, Clark Refining
1998-2001	Golden Key Honor Society
1998-2001	National Association of Collegiate Scholars
1998-2001	National Dean's List
1998-1999	Lambda Sigma Honor Society, Texas A&M University
1997-2001	Academic Achievement Scholarship, Texas A&M University
1997-2001	Dean's Honor Roll, Texas A&M University
1997-2001	Phi Eta Sigma Honor Society, Texas A&M University

## PUBLICATIONS

Klimczak AM, **Crochet JR**. *Cesarean Scar Pregnancy: A Novel Approach to Management*. Journal of Reproductive Medicine 2017 (accepted for publication).

**Crochet JR**, Yeh JS, Price TM. *Operative Hysteroscopy*. Medscape Reference. Updated April 9, 2014. Available at: <http://emedicine.medscape.com/article/1848467-overview>.

Feng Q, **Crochet JR**, Dai Q, Leppert PC, Price TM. *Expression of a mitochondrial progesterone receptor (PR-M) in leiomyomata and association with increased mitochondrial membrane potential*. Journal of Clinical Endocrinology and Metabolism 2014 Mar;99:E390-9.

Yeh JS, **Crochet JR**, Price TM. *Diagnostic Hysteroscopy*. Medscape Reference. Updated July 11, 2013. Available at: <http://emedicine.medscape.com/article/1848258-overview>.

Simel DL, **Crochet JR**, Bastian LA, Chireau MV. Ectopic Pregnancy. In: Simel DL, Rennie D, eds. *The Rational Clinical Examination: Evidenced-Based Clinical Diagnosis*. New York, NY: McGraw-Hill; 2013.

**Crochet JR**, Bastian LA, Chireau MV. *Does this woman have an ectopic pregnancy? The rational clinical examination systematic review*. Journal of the American Medical Association 2013 Apr;309:1722-9.

**Crochet JR**, Shah AA, Schomberg DW, Price TM. *Hyperglycosylated human chorionic gonadotropin does not increase progesterone production by luteinized granulosa cells.* Journal of Clinical Endocrinology and Metabolism 2012 Sep;97:E1741-4.

**Crochet JR**, Peavey MC, Price TM, Behera MA. *Spontaneous pregnancy reaches viability after low first trimester serum progesterone.* Journal of Reproductive Medicine 2012 Mar-Apr;57:171-4.

Lo A, Zheng W, Gong Y, **Crochet JR**, Halvorson LM. *GATA transcription factors regulate luteinizing hormone  $\beta$  (LH $\beta$ ) gene expression.* Journal of Molecular Endocrinology 2011 Jul;47:45-58.

**Crochet JR**, Yeh JS, Clowse MEB, Copland SD. *Late ovarian hyperstimulation syndrome following controlled ovarian stimulation in a woman with systemic lupus erythematosus and lupus nephritis.* Fertility and Sterility 2011 Apr;95:1786.e13-16.

**Crochet JR**, Hawkins KC, Holland DP, Copland SD. *Diagnosis of pelvic tuberculosis in a patient with tubal factor infertility.* Fertility and Sterility 2011 Jan;95:289.e17-20.

Sepilian VP, **Crochet JR**, Nagamani M. *Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens.* Fertility and Sterility 2006 May;85:1441-7.

Walden JL, Garcia H, Hawkins H, **Crochet JR**, Traber L, Gore DC. *Both dermal matrix and epidermis contribute to an inhibition of wound contracture.* Annals of Plastic Surgery 2000 Aug;45:162-6.

## ABSTRACTS

Klimczak AM, Pacheco LE, Massahi N, Richards JP, Kearns WG, Saad A, **Crochet JR**. *The impact of mitochondrial DNA on embryo transfer outcomes.* American Society of Reproductive Medicine 73<sup>rd</sup> Annual Meeting, San Antonio, Texas, October 2017.

Klimczak AM, Pacheco LE, Massahi N, Richards JP, Kearns WG, Saad A, **Crochet JR**. *Lower embryonal mitochondrial DNA content is associated with better quality embryos.* American Society of Reproductive Medicine 73<sup>rd</sup> Annual Meeting, San Antonio, Texas, October 2017.

Diken Z, Rodriguez A, Lin Y, **Crochet JR**. *Timing of embryo transfer after hysteroscopic polypectomy does not affect pregnancy rates.* American Society for Reproductive Medicine 72<sup>nd</sup> Annual Meeting, Salt Lake City, Utah, October 2016.

Dubey AK, Tobler KJ, Massahi N, **Crochet JR**, Kearns WG. *The association between mitochondrial DNA content and implantation potential during IVF and preimplantation genetic screening cycles.* American Society for Reproductive Medicine 72<sup>nd</sup> Annual Meeting, Salt Lake City, Utah, October 2016.

**Crochet JR**, Shah AA, Schomberg DW, Price TM. *Hyperglycosylated human chorionic gonadotropin does not increase progesterone production by luteinized granulosa cells*. Duke University Charles Hammond Research Day, Durham, North Carolina. May 2012.

Ma X, Peavey MC, **Crochet JR**, Leppert PC. *Integrin  $\alpha 11$  expression in human uterine fibroid and myometrium*. Triangle Consortium for Reproductive Biology 21<sup>st</sup> Annual Meeting, Research Triangle Park, North Carolina. March 2012.

**Crochet JR**, Feng Q, Dai Q, Leppert PC, Price TM. *Mitochondrial progesterone receptor (PR-M) distribution in uterine leiomyoma and myometrium and impact on mitochondrial membrane potential ( $\Delta\Psi_m$ ) in immortalized human myometrial cells (hTert-HM)*. American Society for Reproductive Medicine 67<sup>th</sup> Annual Meeting, Orlando, Florida. October 2011.

**Crochet JR**, Hawkins KC, Peavey MC, Price TM, Walmer DK, Copland SD. *Pregnancy in the setting of low and undetectable serum anti-mullerian hormone (AMH)*. Triangle Consortium for Reproductive Biology 20<sup>th</sup> Annual Meeting, Research Triangle Park, North Carolina. March 2011.

**Crochet JR**, Hawkins KC, Peavey MC, Price TM, Walmer DK, Copland SD. *Pregnancy in the setting of low and undetectable serum anti-mullerian hormone (AMH)*. American Society for Reproductive Medicine 66<sup>th</sup> Annual Meeting, Denver, Colorado. October 2010.

Lo A, Gong Y, **Crochet JR**, Zheng W, Halvorson LM. *GATA factors regulate luteinizing hormone (LH)- $\beta$  gene expression*. Society for Gynecologic Investigation 57<sup>th</sup> Annual Meeting, Orlando, Florida. March 2010.

**Crochet JR**, Zheng W, Halvorson LM. *The role of GATA-2 and GATA-3 in the regulation of luteinizing hormone (LH)- $\beta$  gene promoter activity*. American Society for Reproductive Medicine 64<sup>th</sup> Annual Meeting, San Francisco, California. November 2008.

**Crochet JR**, Sepilian VP, Nagamani M. *Leptin, free leptin and soluble leptin receptor levels in women with PCOS and insulin resistance*. National Student Research Forum, Galveston, Texas. April 2005.

**Crochet JR**, Gore DC. *Relative contributions of dermal matrix and epidermis to wound contracture*. The University of Texas Medical Branch Graduate School of Biomedical Sciences, Summer Undergraduate Research Program, Galveston, Texas. July 1998.

## CLINICAL TRIALS

2017-Present	Myovant	MVT-601-3001
	<i>LIBERTY 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered with and without Low-Dose Estradiol and Norethindrone Acetate in Women with Heavy</i>	

*Menstrual Bleeding Associated with Uterine Fibroids*

2016-Present	AbbVie	M12-702	<i>A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Pre-Menopausal Women with Moderate to Severe Endometriosis Associated Pain.</i>
2016-Present	AbbVie	M12-816	<i>Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids.</i>
2016-Present	Beckman Coulter	AMHV02-16	<i>Multi-Center Clinical Evaluation of the Access AMH Assay to Measure AMH as an Aid in the Prediction of Poor Ovarian Response.</i>
2016-Present	ObsEva	16-OBE2109-008	<i>A phase 3, multi-center, randomized, double-blinded, placebo-controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add-back therapy for management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.</i>
2016-Present	ObsEva	15-OBE2109-001	<i>A randomized, double-blind, placebo-controlled, phase 2b dose-ranging study to assess the efficacy and safety of OBE2109 in subjects with endometriosis associated pain.</i>
2015-Present	Ferring		<i>A randomized, Assessor-blind Trial Comparing MENOPUR® (menotropins for injection) and Recombinant FSH (Follicle Stimulating Hormone) in a GnRH Antagonist Cycle with Single-Blastocyst Transfer in a High Responder Subject Population.</i>
2015-2017	Illumina		<i>Prospective, Multi-center, Randomized Controlled Trial Comparing Pregnancy Outcomes Following Selection and Single Embryo Transfer (SET) based on Preimplantation Genetic Screening (PGS) by Next Generation Sequencing (NGS) versus Standard Morphological Assessment.</i>
2015-2016	Merck	MK8342B-061	<i>A Phase 3, single arm, clinical trial to study the contraceptive efficacy and safety of the MK- 8342B (etonogestrel + 17β-estradiol) vaginal ring in healthy women 18 years of age and older, at risk for pregnancy.</i>
2015-Present	AbbVie	M12-821	<i>Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated Pain.</i>
2015-2016	Merck	MK8342B-060	

*A Phase 3 randomized, double-blind, placebo-controlled, trial to study the efficacy and safety of MK-8342B (ENG-E2 vaginal ring) in women with moderate to severe primary dysmenorrhea.*

2015-Present	AbbVie	M12-815	<i>A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Pre-Menopausal Women with Heavy Menstrual Bleeding associated with Uterine Fibroids.</i>
2014- 2017	Ferring		<i>A Phase 3, Open-Label, Non-Randomized, Clinical Trial to Evaluate the Efficacy and Safety of FE999303 (Testosterone Gel) in Adult Hypogonadal Males.</i>
2014-2017	Beckman Coulter		<i>Multi-Center Clinical Feasibility Evaluation of the Access AMH Assay to Measure AMH as an Aid in the Prediction of Poor Ovarian Response to Controlled Ovarian Stimulation.</i>
2014-2016	Actavis	UL1208	<i>A randomized, placebo-controlled, parallel group, multicenter study to evaluate the efficacy and safety of ulipristal acetate for the intermittent treatment of abnormal uterine bleeding associated with leiomyomas.</i>
2014-2015	Repros Therapeutics	ZA-304	<i>A randomized, double, blind, placebo-controlled, multi-center phase III study in men with acquired hypogonadism to compare changes in testosterone and sperm concentration following treatment with the highest dose of Androxal (25 mg) or AndroGel 1.62%.</i>
2014-2016	AbbVie	M12-671	<i>A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy in subjects with moderate to severe endometriosis-associated pain.</i>
2013-2016	Finox Biotech	FIN3002	<i>A phase III investigator and assessor-blinded 1:1 randomized parallel group multi-center study to compare efficacy and safety of two r-hFSH formulations (AFOLIA pen vs. Gonal-F RFF pen) in normal ovulatory women 35-42 years of age undergoing in vitro fertilization.</i>
2013-2015	Nora Therapeutics	NT-03	<i>A randomized, double-blind, multi-center, placebo-controlled study to evaluate the safety, tolerability, and efficacy of multiple doses of NT100 in women undergoing in vitro fertilization (IVF) who have a history of repeated IVF failures.</i>
2012-2016	Abbott Laboratoies	M12-665 Extension	<i>A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of elagolix in subjects with moderate to severe endometriosis associated pain.</i>
2012-2015	Abbott Laboratories	M12-665	

*A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of elagolix in subjects with moderate to severe endometriosis associated pain.*

- 2012-Present Merck MK8175A PN022  
*A phase III, randomized, open-label, active-controlled, multicenter trial to study the contraceptive efficacy and safety of the commercial batch of oral tablets of MK-8175A (norgestrel acetate – 17 $\beta$ estradiol) in healthy, sexually-active women aged 18-50 years.*
- 2012-2014 Repros Therapeutics ZA-300  
*An open label, escalating dose, 6 month phase III safety study of enclomiphene citrate in the treatment of men with secondary hypogonadism (NCT01534208).*

## **RESEARCH EXPERIENCE**

- 2015-Present Department of Obstetrics and Gynecology, the University of Texas Medical Branch, Galveston, Texas  
Projects: In vitro fertilization (IVF), pre-implantation genetic screening, reproductive surgery
- 2012-Present Center of Reproductive Medicine, Webster, Texas  
Projects: In vitro fertilization (IVF), pre-implantation genetic screening, reproductive surgery, endometriosis, uterine fibroids, contraception, male hypogonadism, and female hypogonadism
- 2009-2012 Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina  
Projects: PR-M in fibroids, hCG and progesterone, IVF poor responders  
Mentors: Thomas Price, MD; Susannah Copland, MD; David Walmer, MD/PhD; David Schomberg, PhD
- 2007-2009 Department of Obstetrics and Gynecology, the University of Texas Southwestern Medical Center, Dallas, Texas  
Project: Role of GATA-2 and GATA-3 in LH- $\beta$  promoter activity  
Mentor: Lisa Halvorson, MD
- 2004-2005 Department of Obstetrics and Gynecology, the University of Texas Medical Branch, Galveston, Texas  
Project: Free leptin levels in women with polycystic ovary syndrome  
Mentor: Manubai Nagamani, MD
- 1999-2001 Department of Forest Molecular Biology, Texas A&M University, College Station, Texas  
Project: Gene expression in drought stressed pine trees  
Mentor: Carol Loopstra, PhD

1998 Department of Trauma Services, the University of Texas Medical Branch, Galveston, Texas  
Project: Role of synthetic dermal matrix in prevention of wound contracture  
Mentor: Dennis Gore, MD

1997-1998 Department of Medical Pathology, Texas A&M University, College Station, Texas  
Project: Regulatory factors of angiogenesis  
Mentor: George Davis, MD/PhD

1996-1997 Department of Biochemistry and Biophysics, the University of Texas Medical Branch, Galveston, Texas  
Project: Heavy metal poisoning of the Na<sup>+</sup>/K<sup>+</sup> pump  
Mentor: Malcolm Brodwick, PhD

## RESEARCH GRANTS

2011-2012 Charles Hammond Research Fund, Duke University Medical Center  
*Role of the mitochondrial progesterone receptor (PR-M) in progestin-dependent growth of human fibroids.* Role: Principal Investigator

2011-2012 Charles Hammond Research Fund, Duke University Medical Center  
*The role of various human chorionic gonadotropin isoforms in corpus luteum progesterone production in ectopic and normal pregnancy.* Role: Principal Investigator

## PROFESSIONAL ACTIVITIES

2017-Present Natera IVF Advisory Board  
2012-Present American Medical Association (AMA)  
2012-Present Harris County Medical Society (HCMS)  
2009-Present Society for Reproductive Endocrinology and Infertility (SREI)  
2007-Present American Society for Reproductive Medicine (ASRM)  
2005-Present American Congress of Obstetrics and Gynecology (ACOG)

**LICENSURES AND CERTIFICATIONS** Reproductive Endocrinology and Infertility, ABOG, Board Certified  
Obstetrics and Gynecology, ABOG, Board Certified  
Texas Medical License, M5676

**LANGUAGES** Proficient in medical Spanish.

**PERSONAL** Interests include skiing and snowboarding, music, painting and attending sporting events.

**DISCLOSURES** None